Cerevel Therapeutics skyrockets following CVL-231 results in schizophrenia patients Check out this morning's top movers from around Wall Street, compiled by The Fly.
HIGHER -
- Cerevel Therapeutics (CERE) up 52% after reporting results from its Phase 1b clinical trial of CVL-231, a muscarinic M4-selective Positive Allosteric Modulator, in adult patients with schizophrenia
- Herbalife Nutrition (HLF) up 3% after B. Riley analyst Jeff Van Sinderen initiated coverage of shares with a Buy rating and $70 price target
- PLBY Group (PLBY) up 3% after announcing that it has entered into a definitive agreement to acquire luxury lingerie and lifestyle brand Honey Birdette for $333M in cash and stock
- Boeing (BA) up 1% after United Airlines (UAL) announced the purchase of 270 new Boeing and Airbus (EADSY) aircraft
- Morgan Stanley (MS) and Goldman Sachs (GS) up 3% and 1%, respectively, after both banks increased dividends following Fed stress tests
UP AFTER EARNINGS -
- Jefferies Financial Group (JEF) up 3%
DOWN AFTER EARNINGS -
LOWER -
- Purple Innovation (PRPL) down 8% after cutting Q2 guidance and withdrawing FY21 guidance
- DiaMedica Therapeutics (DMAC) down 24% after reporting interim results from its Phase 2 REDUX trial of DM199 in chronic kidney disease
Symbols:
HLF PLBY BA MS GS JEFJefferies Financial Group
FDS PRPL DMAC CERE Keywords: Fly Intel, Wall Street, Top Stories, Stocks